SLC5A2 and type 2 diabetes mellitus: Most clinical studies have shown that treatment with SGLT2 inhibitors, either as mono- or add-on therapies, significantly decreases both SBP and DBP in patients with type 2 diabetes (Table 1); however, some studies have shown no notable change in DBP (3, 23).